
Sign up to save your podcasts
Or


In this episode of Quality Matters, Tonya Winders, President and CEO of the Global Allergy and Airways Patient Platform (GAAPP), joins host Andy Reynolds to unpack the diagnosis and care gaps that plague asthma treatment—from delayed access to spirometry, to underuse of biologics. Tonya explains what high-quality, patient-centered asthma care requires, and what health care leaders can do to close that gap.
Tonya also discusses:
This podcast is a must-listen for anyone working to redesign care delivery and improve outcomes for patients with chronic respiratory illness.
Key Quote:
“We are finding in that moderate to severe category, when they are diagnosed accurately and get appropriate access to targeted treatments, about one in three go into a clinical remission, where they have no exacerbations, no symptoms, no hospital, no ER, no oral corticosteroids, no use of short acting bronchodilator.
This is something that, I have to tell you, I never dreamt would come in my career. So, it's very exciting, especially for those that have had the opportunity to access these miracle drugs—that’s the term they use, miracle drugs—that have changed their lives and given them the freedom to breathe.”
Tonya Winders
Time Stamps:
Links:
NCQA White Paper: Improving Outcomes for People with Asthma
Connect with Tonya Winders
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By NCQA4.6
3535 ratings
In this episode of Quality Matters, Tonya Winders, President and CEO of the Global Allergy and Airways Patient Platform (GAAPP), joins host Andy Reynolds to unpack the diagnosis and care gaps that plague asthma treatment—from delayed access to spirometry, to underuse of biologics. Tonya explains what high-quality, patient-centered asthma care requires, and what health care leaders can do to close that gap.
Tonya also discusses:
This podcast is a must-listen for anyone working to redesign care delivery and improve outcomes for patients with chronic respiratory illness.
Key Quote:
“We are finding in that moderate to severe category, when they are diagnosed accurately and get appropriate access to targeted treatments, about one in three go into a clinical remission, where they have no exacerbations, no symptoms, no hospital, no ER, no oral corticosteroids, no use of short acting bronchodilator.
This is something that, I have to tell you, I never dreamt would come in my career. So, it's very exciting, especially for those that have had the opportunity to access these miracle drugs—that’s the term they use, miracle drugs—that have changed their lives and given them the freedom to breathe.”
Tonya Winders
Time Stamps:
Links:
NCQA White Paper: Improving Outcomes for People with Asthma
Connect with Tonya Winders
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

31,989 Listeners

30,706 Listeners

43,602 Listeners

112,037 Listeners

56,517 Listeners

493 Listeners

1,150 Listeners

5,455 Listeners

196 Listeners

6,066 Listeners

4,486 Listeners

390 Listeners

15,840 Listeners

2,204 Listeners

1,670 Listeners